CD86 Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression

Figure 9

Performance comparison of IRS and TIDE (a) IRS survival curve and ROC curve of dataset IMvigor210; (b) TIDE survival curve and ROC curve of dataset IMvigor210; (c) ROC curves of IRS and TIDE effect on immunotherapy in dataset IMvigor210; (d) IRS survival curve and ROC curve of dataset GSE91061; (e) TIDE survival curve and ROC curve of dataset GSE91061; (f) ROC curve of IRS and TIDE effect on immunotherapy in dataset GSE91061; (g) IRS survival curve and ROC curve of dataset GSE78220; (h) TIDE survival curve and ROC curve of dataset GSE78220; (i) ROC curves of IRS and TIDE effect on immunotherapy in dataset GSE78220; (j) IRS survival curve and ROC curve of dataset GSE135222; (k) TIDE survival curve and ROC curve of dataset GSE135222; (l) ROC curves of IRS and TIDE effects on immunotherapy in dataset GSE135222.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)